Safer Personalised Cancer Treatment Digital Follow-up

Launched by NORDLANDSSYKEHUSET HF · Jun 20, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Safer Personalised Cancer Treatment Digital Follow-up," aims to explore how a digital program that allows cancer patients to report their symptoms can improve their treatment experience. Specifically, it will compare two groups of patients receiving immunotherapy, a type of cancer treatment. One group will use a digital system to share their symptoms directly with healthcare providers, while the other group will continue with standard follow-up procedures. The researchers want to find out if the digital approach leads to fewer and less severe side effects from the treatment and whether it affects patients' quality of life and survival rates.

To be eligible for this trial, participants must be at least 18 years old and have a cancer diagnosis, receiving immunotherapy as part of their treatment. However, individuals with blood cancers or gynecological cancers cannot participate. If you join the trial, you will be closely monitored for any side effects and overall health, helping researchers understand the benefits of this personalized digital follow-up program. The study is currently recruiting participants, and your involvement could contribute to improving cancer care for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Above 18 years of age
• • Cancer diagnosis as primary or secondary diagnosis according to the ICD-10 classification
• • Receiving immunotherapy as systemic anticancer treatment reported with ATC codes for medications.
• Exclusion Criteria:
• • Hematological cancer
• • Gynecological cancer